Company: GIFLF
Filing Date: 2025-11-04
Form Type: 6-K
Source: 0001104659-25-106104
Chunk: 1

Company: Grifols SA
Filing Date: 2025-11-04
Form: 6-K
Chunk 1
---
 in the previous year, while liquidity remains robust 
 at EUR 1,475 million                                                                           |

| · | At                                                                                        
 Guidance FX rates (as per guidance from the Capital Markets Day 3),                       
 improved revenue and FCF pre-M&A pre-dividends guidance and maintained Adjusted EBITDA    
 guidance. Full year FX headwinds estimated to be EUR c.70 million for Adjusted EBITDA and 
 broadly neutral for free cash flow and leverage                                           |

Barcelona, November 4, 2025-Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today reported its third quarter 2025 results, continued delivery of the Value Creation Plan.

Revenues for the first nine months of the year rose by 7.7% cc to EUR 5,542 million supported by a 9.1% cc growth in the third quarter, to EUR 1,865 million, mainly driven by the Biopharma business. Adjusted EBITDA year-to-date stood at EUR 1,358 million with a 24.5% margin, supported by a third quarter of EUR 482 million, 8.8% cc higher than in the same period last year, representing a margin of 25.8%.

Grifols registered a net profit of EUR 304 million year-to-date, up 245% compared to the same period of 2024, supported by a total of EUR 127 million in the third quarter, an increase of 146%, in line with the previous quarter. Free cash flow pre-M&A pre-dividend reached EUR 203 million in the third quarter, resulting in EUR 188 million for the first nine months of the year. This represents a EUR 257 million year-over-year improvement, mostly driven by EBITDA expansion, lower CAPEX and cash interest costs.

Grifols continues to strengthen its free cash flow generation and continued deleveraging focus. The leverage ratio stands at 4.2x, down from 5.1x in the same period of 2024, and liquidity position increased to EUR 1,475 million.

| 1 | Operating                                                                          
 or constant currency (cc) excludes changes rate variations reported in the period. |

| 2 | Calculated                                                                                    
 as EBITDA Adjusted - Net Working Capital - CAPEX (including capitalized IT and R&D, and       
 extraordinary growth CA